1. Validation of the monocyte activation test with three therapeutic monoclonal antibodies
- Author
-
Ruth, Daniels, Wim, Van der Elst, Nele, Dieltjens, Tinne, Appels, Chi K, So, Thomas, Nys, Liesbeth, Voeten, Philip, Breugelmans, Marijke W A, Molenaar-de Backer, Eelo, Gitz, Stephen, Poole, and Mehul, Patel
- Subjects
Endotoxins ,Pharmacology ,Medical Laboratory Technology ,Pyrogens ,Leukocytes, Mononuclear ,Animals ,Antibodies, Monoclonal ,Rabbits ,General Medicine ,Animal Testing Alternatives ,Monocytes - Abstract
Pharmaceutical products intended for parenteral use must be free from pyrogenic (fever-inducing) contamination. Pyrogens comprise endotoxins from Gram-negative bacteria and non-endotoxin pyrogens from Gram-positive bacteria, viruses, and fungi. The longstanding compendial test for pyrogens is the rabbit pyrogen test, but in 2010 the monocyte acti-vation test (MAT) for pyrogenic and pro-inflammatory contaminants was introduced into the European Pharmacopoeia (Ph. Eur.) as a non-animal replacement for the rabbit pyrogen test. The present study describes the first product-specific Good Manufacturing Practice validation of Ph. Eur. MAT, Quantitative Test, Method A for the testing of three therapeutic monoclonal antibodies. The study used the MAT version with cryo-preserved peripheral blood mononuclear cells and interleukin-6 as the readout. Much of the data presented here for one of the antibodies was included in a successful product license application to the European Medicines Agency.
- Published
- 2022
- Full Text
- View/download PDF